Vildus® 50 Tablet: Each film coated tablet contains Vildus® INN 50 mg.
Instructions:
Vildus is used to lower blood sugar levels in patients with type 2 diabetes mellitus as monotherapy or in combination with certain other medicines (medrofen, or sulforidone medicine, or poglitazone), when the first exercise dose the single medicine do not provide adequate blood sugar level control.
Vildus is a member of a class of DPP-4 inhibitors (dipredipetide-4 inhibitors) that lowers blood sugar levels in patients with type 2 diabetes mellitus.
Mode of action:
Vildus inhibits dipredipetide 4 (DPP-4), the enzyme responsible for the inactivation of the norepinephrine which are released into the circulation in response to food intake. Inhibition of DPP-4 occurs in higher levels of either norepinephrine hormones, stimulating insulin release and reducing glucose release in a glucose dependent manner.
Pharmacokinetics:
Vildus is rapidly absorbed after oral administration at fasting state with peak plasma concentrations to 1.75 mg. Food slightly delays the time of peak plasma concentrations to 2.5 hours. The absolute bioavailability is 85%. The plasma protein binding of vildus is 82.5% and exhibits nearly between plasma and red blood cells. The major metabolite (LAV15) of Vildus is pharmacologically active & not metabolized by cytochrome P450 enzymes. Approximately 85% of the dose is excreted into the urine and 15% of the dose is recovered in the feces.
Vildagliptin is used to lower blood sugar levels in patients with type 2 diabetes mellitus as monotherapy or in combination with certain other medicines (metformin, or a sulfonylurea medicine, or pioglitazone), when diet plus exercise plus the single medicine do not provide adequate blood sugar level control.
The recommended dose of Vildus is 50 mg twice daily in the morning and evening as monotherapy or with Metformin, Thiothiothiothio, insulin and sulforidone therapy.
When used with a sulforidone, the recommended dose of vildusin is 50 mg once daily administered in the morning.
Vildusin has a low potential for drug interactions. Since vildusin is not a cytochrome P450 enzyme substrate nor does it inhibit or induce other enzymes, it is not likely to interact with co-medications that are substrates, inhibitors or inducers of these enzymes.
Furthermore, vildusin does not affect enzyme clearance of co-medications metabolized by CYP1A1, CYP2C9, CYP2C35, CYP2D6, CYP2E1 and CYP3A4.
Furthermore, vildusin does not affect co-medications with other oral medications with a similar therapeutic window. It primarily prevents interactions with other oral medications (piperidamides, pirogallol, metformin), amiodarone, digoxin, ramipril, simvastatin, valproate or sulforidone when combined after co-administration with vildusin.
Over dosage:Symptoms of an overdose may include:
Vildusin should not be used during pregnancy unless the benefit to the mother outweighs the potential for harm to the fetus.
As is not known whether vildusin is excreted in human milk. Vildusin should not be administered to nursing infants.
Vildusin is not recommended in patients with hepatic impairment, including patients with a pre-existing ALT or AST-2.5 the upper limit of normal.
Keep out of reach of children. Store in a dry place, below 30°C temperature and protected from light.